Join the Alzheimer's Association on October 17th for a webinar and live panel discussion on recent late-stage trial readouts, the broader treatment landscape, and considerations for research and clinical communities. The event will include a conversation about clinical safety and the future of the clinical community.
This will be a 1-hour event, with live panel discussions (featuring the Founding Director of ATRI, Paul Aisen, M.D.) and interactive Q&A opportunities for attendees.
Monday, October 17, 2022
12 p.m. ET/ 11 a.m. CT / 9 a.m. PT
Panelists include**:
Paul Aisen, M.D.; Maria C. Carrillo, Ph.D.; Ronald Petersen, M.D., Ph.D.; Dennis Selkoe, M.D.; Liana Apostolova, M.D., MSc, FAAN; Stephen Salloway, M.D., M.S.; Gil Rabinovici, M.D.; Alireza Atri, M.D., Ph.D and Marwan Sabbagh M.D.
**Individual speakers' conflicts of interest will be shared during the discussion.
The Alzheimer’s Association forges partnerships with all those with the shared commitment to end Alzheimer’s and other dementia, including Alzheimer’s organizations around the globe, the National Institutes of Health, National Institute on Aging, universities, corporations, and the pharmaceutical, biotech and device industries. With our broad partnerships, we are committed to transparency. The Alzheimer’s Association received 0.70 percent of its total 2021 contributed revenue from the biotechnology, pharmaceutical, diagnostics and clinical research industries. This and additional information can be found at www.alz.org/about/transparency.